# US 2017/0253666 A1 · Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253666 A1
- Document ID: US20170253666A1
- Status: Published application
- Kind: A1
- Application number: 15/446,720
- Filed: 2017-03-01
- Published: 2017-09-07
- Earliest claimed: 2016-03-03
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Viktoria Gusarova; Jesper Gromada; Andrew J. Murphy
- Web page: https://patentgrep.com/patent/US20170253666A1

## CPC

- C07K 16/40: against enzymes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-PCSK9 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

## Claims

### Claim 1

A method of treating a patient suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy, the method comprising treating the patient with a combination of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and an inhibitor of angiopoietin-like protein 3 (ANGPTL3).

### Claim 2 (depends on 1)

The method of claim 1, wherein the hypercholesterolemia is heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH).

### Claim 3 (depends on 1)

The method of claim 1, wherein the PSCK9 inhibitor is an antibody, or an antigen-binding fragment thereof, that binds specifically to PCSK9.

### Claim 4 (depends on 3)

The method of claim 3, wherein the PCSK9 antibody is administered to the patient at a dose of about 75 mg at a frequency of once every two weeks.

### Claim 5 (depends on 3)

The method of claim 3, wherein the PCSK9 antibody is administered to the patient at a dose of about 140 mg at a frequency of once every two weeks.

### Claim 6 (depends on 3)

The method of claim 3, wherein the PCSK9 antibody is administered to the patient at a dose of about 150 mg at a frequency of once every two weeks, or once every four weeks.

### Claim 7 (depends on 3)

The method of claim 3, wherein the PCSK9 antibody is administered to the patient at a dose of about 300 mg at a frequency of once every four weeks.

### Claim 8 (depends on 3)

The method of claim 3, wherein the PCSK9 antibody is administered to the patient at a dose of about 420 mg at a frequency of once every four weeks.

### Claim 9

The method of claim, 3, wherein the PCSK9 antibody is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, and ralpancizumab.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antibody is alirocumab.

### Claim 11 (depends on 3)

The method of claim 3, wherein the antibody or antigen-binding fragment thereof that binds specifically to PCSK9 comprises the complementary determining regions (CDRs) of a heavy chain variable (HCVR) having the amino acid sequence of SEQ ID NO: 12 and the CDRs of a light chain variable region (LCVR) of SEQ ID NO: 17.

### Claim 12 (depends on 3)

The method of claim 3, wherein the antibody or antigen-binding fragment thereof that binds specifically to PCSK9 comprises a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 13, a HCDR2 having the amino acid sequence of SEQ ID NO: 14, a HCDR3 having the amino acid sequence of SEQ ID NO: 15, a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 18, a LCDR2 having the amino acid sequence of SEQ ID NO: 19, and a LCDR3 having the amino acid sequence of SEQ ID NO: 21.

### Claim 13 (depends on 3)

The method of claim 3, wherein the antibody or antigen-binding fragment thereof that binds specifically to PCSK9 comprises a HCVR having the amino acid sequence of SEQ ID NO: 12 and a LCVR having the amino acid sequence of SEQ ID NO: 17.

### Claim 14 (depends on 3)

The method of claim 3, wherein the PCSK9 antibody is administered to the patient subcutaneously or intravenously.

### Claim 15 (depends on 1)

The method of claim 1, wherein the ANGPTL3 inhibitor is an antibody, or an antigen-binding fragment thereof, that binds specifically to ANGPTL3.

### Claim 16 (depends on 15)

The method of claim 15, wherein the ANGPTL3 antibody is administered to the patient at a dose of about 150 mg at a frequency of once every week.

### Claim 17 (depends on 15)

The method of claim 15, wherein the ANGPTL3 antibody is administered to the patient at a dose of about 300 mg at a frequency of once every week.

### Claim 18 (depends on 15)

The method of claim 15, wherein the ANGPTL3 antibody is administered to the patient at a dose of about 450 mg at a frequency of once every week.

### Claim 19 (depends on 15)

The method of claim 15, wherein the ANGPTL3 antibody is administered to the patient at a dose of about 300 mg at a frequency of once every two weeks.

### Claim 20 (depends on 15)

The method of claim 15, wherein the ANGPTL3 antibody is administered to the patient at a dose of about 450 mg at a frequency of once every two weeks.

### Claim 21 (depends on 15)

The method of claim 15, wherein the ANGPTL3 antibody is administered to the patient at a dose of about 20 mg/kg at a frequency of once every four weeks.

### Claim 22 (depends on 15)

The method of claim 15, wherein the ANGPTL3 antibody is evinacumab.

### Claim 23 (depends on 15)

The method of claim 15, wherein the antibody or antigen-binding fragment thereof that binds specifically to ANGPTL3 comprises the complementary determining regions (CDRs) of a heavy chain variable (HCVR) having the amino acid sequence of SEQ ID NO: 2 and the CDRs of a light chain variable region (LCVR) of SEQ ID NO: 3.

### Claim 24 (depends on 15)

The method of claim 15, wherein the antibody or antigen-binding fragment thereof that binds specifically to ANGTL3 comprises a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 4, a HCDR2 having the amino acid sequence of SEQ ID NO: 5, a HCDR3 having the amino acid sequence of SEQ ID NO: 6, a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO:
7, a LCDR2 having the amino acid sequence of SEQ ID NO: 8, and a LCDR3 having the amino acid sequence of SEQ ID NO: 9.

### Claim 25 (depends on 15)

The method of claim 15, wherein the antibody or antigen-binding fragment thereof that binds specifically to ANGPTL3 comprises a HCVR having the amino acid sequence of SEQ ID NO: 2 and a LCVR having the amino acid sequence of SEQ ID NO: 3.

### Claim 26 (depends on 15)

The method of claim 15, wherein the ANGPTL3 antibody is administered to the patient subcutaneously or intravenously.

### Claim 27 (depends on 1)

The method of claim 1, wherein the treating with a combination of a PCSK9 inhibitor and an inhibitor of ANGPTL3 results in lowering one or more of the following parameters:
(a) a reduction in serum total cholesterol (TC) level;
(b) a reduction in serum low-density lipoprotein cholesterol (LDL-C) level; and
(c) a reduction in serum non-high density lipoprotein cholesterol (non-HDL-C) level
in the patient, wherein the reduction of (a), (b), and/or (c) is determined relative to the patient's serum TC level, serum LDL-C level, and/or serum non-HDL-C level prior to, or at the time of initiation of, treatment with the combination of the PCSK9 inhibitor and the ANGPTL3 inhibitor.
